TriangleNCT05510908 · OUTCOME
Describe the Cancer Diagnostics of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Baseline
What was measured
The distribution of participant cancer diagnosis variable will be summarized.
Analysis population: Participants who enrolled in this study
Groups in this outcome
New, Primary or Recurrent Disease
Considering or currently receiving cancer treatment Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
Metastic or Locally Advanced Cancer
This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
Prior Cancer
Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
| Group | Source count |
|---|---|
| New, Primary or Recurrent Disease | 268 |
| Metastic or Locally Advanced Cancer | 33 |
| Prior Cancer | 159 |
Reported measurements
Hematologic malignancy
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| New, Primary or Recurrent Disease | 86 | Not reported | Not reported | Not reported | Not reported |
| Metastic or Locally Advanced Cancer | 1 | Not reported | Not reported | Not reported | Not reported |
| Prior Cancer | 53 | Not reported | Not reported | Not reported | Not reported |
Kaposi Sarcoma
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| New, Primary or Recurrent Disease | 85 | Not reported | Not reported | Not reported | Not reported |
| Metastic or Locally Advanced Cancer | 4 | Not reported | Not reported | Not reported | Not reported |
| Prior Cancer | 20 | Not reported | Not reported | Not reported | Not reported |
Solid Tumors associated with HPV infection
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| New, Primary or Recurrent Disease | 30 | Not reported | Not reported | Not reported | Not reported |
| Metastic or Locally Advanced Cancer | 7 | Not reported | Not reported | Not reported | Not reported |
| Prior Cancer | 36 | Not reported | Not reported | Not reported | Not reported |
Solid Tumors unrelated to HPV
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| New, Primary or Recurrent Disease | 60 | Not reported | Not reported | Not reported | Not reported |
| Metastic or Locally Advanced Cancer | 20 | Not reported | Not reported | Not reported | Not reported |
| Prior Cancer | 48 | Not reported | Not reported | Not reported | Not reported |
Unknown
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| New, Primary or Recurrent Disease | 7 | Not reported | Not reported | Not reported | Not reported |
| Metastic or Locally Advanced Cancer | 1 | Not reported | Not reported | Not reported | Not reported |
| Prior Cancer | 2 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 86
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 53
- title
- Hematologic malignancy
- categories
- measurements
- group Id
- OG000
- value
- 85
- group Id
- OG001
- value
- 4
- group Id
- OG002
- value
- 20
- title
- Kaposi Sarcoma
- categories
- measurements
- group Id
- OG000
- value
- 30
- group Id
- OG001
- value
- 7
- group Id
- OG002
- value
- 36
- title
- Solid Tumors associated with HPV infection
- categories
- measurements
- group Id
- OG000
- value
- 60
- group Id
- OG001
- value
- 20
- group Id
- OG002
- value
- 48
- title
- Solid Tumors unrelated to HPV
- categories
- measurements
- group Id
- OG000
- value
- 7
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 2
- title
- Unknown
- denoms
- counts
- group Id
- OG000
- value
- 268
- group Id
- OG001
- value
- 33
- group Id
- OG002
- value
- 159
- units
- Participants
- description
- The distribution of participant cancer diagnosis variable will be summarized.
- groups
- description
- Considering or currently receiving cancer treatment Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
- id
- OG000
- title
- New, Primary or Recurrent Disease
- description
- This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
- id
- OG001
- title
- Metastic or Locally Advanced Cancer
- description
- Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
- id
- OG002
- title
- Prior Cancer
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- Participants who enrolled in this study
- reporting Status
- POSTED
- time Frame
- Baseline
- title
- Describe the Cancer Diagnostics of Cancer Patients With HIV Receiving Care at Domestic AMC Sites.
- type
- OTHER_PRE_SPECIFIED
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice